Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 1, 2000, Pages 5-8

  Ye, Zhixiong ^a   Gao, Yingduo ^a   Bakshi, Raman K ^a   Chen, Meng Hsin ^a   Rohrer, Susan P ^a   Feighner, Scott D ^a   Pong, Sheng Shung ^a   Howard, Andrew D ^a   Blake, Allan ^a   Birzin, Elizabeth T ^a   Locco, Louis ^a   Parmar, Rupa M ^a   Chan, Wanda W S ^a   Schaeffer, James M ^a   Smith, Roy G ^a   Patchett, Arthur A ^a   Nargund, Ravi P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE DERIVATIVE; IBUTAMOREN; QUINAZOLINONE DERIVATIVE;

ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HORMONE RECEPTOR INTERACTION; HYDROPHOBICITY; PHARMACOPHORE;

ANIMALS; BINDING SITES; DRUG DESIGN; HUMAN GROWTH HORMONE; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, MOLECULAR; QUINAZOLINES; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SECRETORY RATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034598364     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00584-3     Document Type: Article

References (12)

1. Rosen T., Johannsson G., Johannsson J.-O., Bengtsson B.-A. Horm. Res. 43:1995;93.
2. Strobl, J. S.; Thomas, M. J. Pharmacol. Rev. 1993, 46.
3. 35S] MK-0677 as radiolabeled ligand (ref 9).
4. Rat pituitary cell GH release assay - Test compounds incubated with cultured rat pituitary cells for 15 min at 37°C; GH release in culture medium measured using GH radioimmunoassay (ref, Cheng. K.; Chan, W. W.-S.; Barreto, A.; Convey, E. M.; Smith, R. G. Endocrinology 1989, 124, 2791).
5. Bowers C.Y., Mommany F.A., Reynolds G.A., Hong A. Endocrinol. 114:1984;1537.
6. For a summary please see: Nargund, R. P.; Patchett, A. A.; Bach, M. A.; Murphy, M. G.; Smith, R. G. J. Med. Chem. 1998, 41, 1.
7. Patchett A.A., Nargund R.P., Tata J.R., Chen M.-H., Barakat K.J., Johnston D.B.R., Cheng K., Chan W. W.-S., Butler B.S., Hickey G., Jacks T., Schleim K., Pong S.-S., Chaung L.Y.-P., Chen H.Y., Frazier E., Leung K.H., Chiu S.-H.L., Smith R.G. Proc. Natl. Acad. Sci. USA. 92:1995;7001.
8. Carpino, P. A.; Jardine, D. P. A.; Lefker, B. A.; Ragan, J. A. PCT Patent Publication WO97/24369.
9. Similar improvements were observed earlier in imidazopyridine and benzimidazole series and the results will be published by Bakshi, R. K. and Chen, M.-C.
10. Howard A.D., Feighner S.D., Cully D.F., Arena J.P., Liberator P.A., Rosenblum C.I., Hamelin M., Hreniuk D.L., Palyha O.C., Anderson J., Paress P.S., Diaz C., Chou M., Liu K.K., McKee K.K., Pong S.-S., Chaung L.-Y.P., Elbrecht A., Dashkevicz M., Heavens R., Righy M., Sirinathsinghji D.J.S., Dean D.C., Melillo D.G., Patchett A.A., Nargund R.P., Griffin P.R., DeMartino J.A., Gupta S.K., Shaeffer J.M., Smith R.G., Van der Ploeg L.H.T. Science. 273:1996;974.
11. Feighner S.D., Howard A.D., Prendergast K., Palyha O.C., Hreniuk D.L., Nargund R.P., Underwood D., Tata J.R., Dean D.C., Tan C., McKee K.K., Woods J.W., Patchett A.A., Smith R.G., Van der Ploeg L.H.T. Mol. Endocrinol. 12:1998;137.
12. Modeling of compounds 2, 16 and 21 was carried out using the MMFFs force field (ref. Halgren T. A. J. Comput. Chem. 1999, 20, 720). Conformational generation and minimization in accord with solution NMR structure of GHRP-6 (Baum, M. W., Merck Research Laboratories) were performed and low energy structures which fit the constraints were used in the docking studies.